Antidepressants for generalised anxiety disorder (GAD)

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  Kapczinski, Flávio ^a   dos Santos Souza, Juliano J S S ^b   Batista Miralha da Cunha, Angelo A B C ^b   Schmitt, Ricardo R S ^c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

CLINICAL STUDY; GENERALIZED ANXIETY DISORDER; HUMAN; REVIEW; STUDY WITHDRAWAL; SYSTEMATIC REVIEW; ANXIETY DISORDERS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84961926947     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003592.pub2     Document Type: Review

References (35)

1. Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Journal of Clinical Psychiatry 1999;60(8):528-35.
2. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder. JAMA 2000;283(23):3082-8.
3. Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. Journal of Clinical Psychiatry 2001;62(11):888-93.
4. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalized anxiety disorder. British Journal of Psychiatry 2001;179:15-22.
5. Hackett D, Desmet A, Salinas EO. Dose-response efficacy of long-term treatment of venlafaxine extended-release in generalized anxiety disorder. Journal of the European College of Neuropsychopharmacology 9[Suppl 5], 315. 1999 1999;9(Suppl 5):315.
6. Hackett D, Salinas E. A six-month evaluation of three dose levels of venlafaxine extended-released in nondepressed outpatients with GAD. 152nd Annual Meeting of the American Psychiatric Association. Washington DC, USA. 15 20th May. 1999.
7. Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. Journal of Clinical Psychiatry 2001;62(11):888-93.
8. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew K, Burnham DB, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 2001;62(5):350-7.
9. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry 1993;50(11):884-95.
10. Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. Journal of Clinical Psychiatry 2001;62(11):888-93.
11. Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended release venlafaxine in nondepressed outpatients with generalized anxiety disorder. American Journal of Psychiatry 2000;157(6):968-74.
12. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatrica Scandinavica 1997;95(5):444-50.
13. Rynn M, Siqueland L, Rickels K, Garcia Espana F. Treatment outcome of children with anxiety disorders. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10-14; San Juan; Puerto Rico. 2000.
14. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. American Journal of Psychiatry 2001;158(12):2008-14.
15. Hedges DW, Reimherr FW, Strong RE, Halls CH, Rust C. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacology Bulletin 1996;32(4):671-6.
16. Frith CD, Stevens M, Johnstone EC, Owens DG. The effects of chronic treatment with amitriptyline and diazepam on electrodermal activity in neurotic outpatients. Physiological Psychology 1984;12(3):247-52.
17. Johnstone EC, Bourne RC, Crow TJ, Frith CD, Gamble S, Lofthouse R, et al. The relationships between clinical response, psychophysiological variables and plasma levels of amitriptyline and diazepam in neurotic outpatients. Psychopharmacology 1981;72(3):233-40.
18. Johnstone EC, Owens DG, Frith CD, McPherson K, Dowie C, Gold A. Neurotic Illness and its response to anxiolytic and antidepressant treatment. Psychological Medicine 1980;10(2):321-8.
19. Kahn RJ, McNair DM, Lipman RS, Covi L, Rickels K, Downing R, et al. Imipramine and Chlordiazepoxide in depressive and anxiety disorders. Archives of General Psychiatry 1986;43(1):79-85.
20. Lipman RS, Covi L, Rickels K, McNair DM, Downing R, Kahn RJ, et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders. I. Efficacy in depressed outpatients. Archives of General Psychiatry 1986;43(1):68-77.
21. Rickels K, DeMartinis N, Garcia-España F, Greenblatt DJ, Mandos LA, Rynn M. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. American Journal of Psychiatry 2000;157(12):1973-9.
22. Wingerson D, Nguyen C, Roy-Byrne PP. Chlomipramine treatment for generalized anxiety disorder. Journal of Clinical Psychopharmacology 1992;12(3):214-5.
23. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. Journal of Clinical Psychiatry 1988;49(8):293-301.
24. American Psychiatric Association. Diagnostic and Statistical manual of mental disorders: DSM-IV. Washington DC: American Psychiatric Association, 1994.
25. Berrios GE, Link C. Anxiety disorders - clinical section. A history of clinical psychiatry. London: Atlone, 1995:545-62.
26. Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. Journal of Clinical Psychiatry 2001;62(Suppl 11):15-9.
27. Brawman-Mintzer O. Pharmacological treatment of generalized anxiety disorder. Psychiatric Clinics of North America 2001;24(1):119-37.
28. Clarke M, Oxman AD. Cochrane Reviewers' Handbook. Oxford: Update Software, 2000.
29. Hackett D. Venlafaxine XR in the treatment of anxiety. Acta Psychiatrica Scandinavica. Supplementum 2000;406:30-5.
30. Hunt CJ. The current status of the diagnostic validity and treatment of generalized anxiety disorder. Current Opinion in Psychiatry 2002;15(2):157-62.
31. Judd LL, Kessler RC, Paulus MP. Comorbidity as a fundamental feature of generalized anxiety disorders: results form the National Comorbidity Survey (NCS). Acta Psychiatrica Scandinavica, Supplementum 1998;393:6-11.
32. Kendell RE. The role of diagnosis in psychiatry. Oxford: Blackwell, 1975:67-8.
33. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. American Journal of Psychiatry 1993;150(4):600-7.
34. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the national comorbidity survey. Archives of General Psychiatry 1994;51(5):355-64.
35. Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalized anxiety disorder. British Journal of Psychiatry 1996;168:308-13.